Aquestive Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for AQST, updated each market day.
AQST AI Sentiment
AI sees no strong directional signal for Aquestive Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: May 14, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Aquestive Therapeutics, Inc. Common Stock
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Sector
Exchange
Market Cap
$525,723,612
Cap Tier
Employees
147
Headquarters
WARREN, NJ
Listed Since
July 25, 2018
Website
AQST Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
AQST Volatility
Aquestive Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
